Prestige Biologics Co., Ltd.

KOSDAQ:A334970 Stock Report

Market Cap: ₩435.1b

Prestige Biologics Valuation

Is A334970 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A334970 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A334970's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A334970's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A334970?

Key metric: As A334970 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A334970. This is calculated by dividing A334970's market cap by their current book value.
What is A334970's PB Ratio?
PB Ratio6x
Book₩71.68b
Market Cap₩435.09b

Price to Book Ratio vs Peers

How does A334970's PB Ratio compare to its peers?

The above table shows the PB ratio for A334970 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.1x
A144510 GC Cell
0.8xn/a₩395.2b
A064550 Bioneer
2.4x97.6%₩522.7b
A347850 D&D Pharmatech
4.8xn/a₩361.6b
A199800 ToolGen
16.6xn/a₩310.2b
A334970 Prestige Biologics
6xn/a₩435.1b

Price-To-Book vs Peers: A334970 is good value based on its Price-To-Book Ratio (6x) compared to the peer average (6.1x).

Price to Book Ratio vs Industry

How does A334970's PB Ratio compare vs other companies in the KR Biotechs Industry?

5 CompaniesPrice / BookEstimated GrowthMarket Cap
A377740 BioNote
0.3xn/aUS$344.40m
A950210 Prestige BioPharma
0.4xn/aUS$138.51m
A109960 AP Healthcare
0.3xn/aUS$68.27m
A950220 NeoImmuneTech
0.4xn/aUS$17.20m
A334970 6.0xIndustry Avg. 2.5xNo. of Companies12PB0246810+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A334970 is expensive based on its Price-To-Book Ratio (6x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A334970's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A334970 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A334970's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩282,000.00

7D

6.8%

1Y

76.9%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,210.00

7D

-5.0%

1Y

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩132,000.00

7D

3.4%

1Y

-38.6%